RecruitingNot ApplicableNCT05089149

Chronic Heart Failure - COngestion eValuation

Évaluation de la Congestion en Ambulatoire Chez Les Patients Atteints d'Insuffisance Cardiaque Chronique. CHF-COV (Chronic Heart Failure - COngestion eValuation)


Sponsor

Pr. Nicolas GIRERD

Enrollment

200 participants

Start Date

Dec 14, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

Heart failure (HF) is a significant cause of death and the leading cause of hospitalization in patients over 65 years of age. Congestion is the main source of symptoms and the leading cause of hospitalization for HF. Furthermore, congestive signs identified in asymptomatic patients are associated with the risk of developing symptomatic HF. The literature supports a multi-modality / integrative evaluation of congestion, combining clinical examination, laboratory results and ultrasound evaluation. The main objective of the CHF-COV study is to identify congestion markers (clinical, biological and ultrasound) quantified during a consultation or day hospitalization for the monitoring of chronic HF that are associated with the risk of all-cause death or hospitalization for acute HF within 24 months after day hospitalization.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is evaluating whether lung ultrasound (a non-invasive bedside scan) can accurately measure fluid buildup (congestion) in people with chronic heart failure. It aims to see if this easy imaging tool can help doctors better monitor and manage heart failure. **You may be eligible if...** - You have been diagnosed with chronic heart failure - You are being seen in hospital for a scheduled visit or consultation (not an emergency) - You are 18 or older - You have signed the informed consent form **You may NOT be eligible if...** - You are expected to live fewer than 3 months due to another serious illness - You are on dialysis or have very poor kidney function - You have had lung surgery to remove a lobe or an entire lung - You have severe lung disease that would make ultrasound imaging unreliable (such as severe emphysema or pulmonary fibrosis) - You are pregnant, breastfeeding, or under legal protection measures Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREClinical examination centered on congestion

Clinical examination (including the EVEREST, ASCEND and Ambrosy scores) centered on congestion will be performed during day hospitalization or consultation

PROCEDURECardiac, pulmonary, peritoneal, jugular, renal Doppler ultrasounds and liver elastography

Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds will be performed during day hospitalization or consultation/ peritoneal, jugular and renal Doppler ultrasounds and liver elastography are optional

PROCEDUREBlood sample retrieved for biological assessment and biobanking

Blood sample retrieved for biological assessment and biobanking will be performed during day hospitalization or consultation

OTHERTelephone follow-up

Telephone follow-up will be performed 3, 12 and 24 months after visit (during day hospitalization or consultation)

BEHAVIORALKansas City Cardiomyopathy Questionnaire (KCCQ)

Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge


Locations(2)

CHRU de Nancy

Vandœuvre-lès-Nancy, France

CHRU de Nancy

Vandœuvre-lès-Nancy, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05089149


Related Trials